Business Wire

NC-PERCONA

23.5.2023 15:01:36 CEST | Business Wire | Press release

Share
The Percona 2023 State of Open Source Database Survey Reveals Reluctance Among Businesses to Alter Database Strategies in the Face of Economic Uncertainty

Percona, a leader in enterprise-grade open source database software, support, and services, today announced the initial findings of its State of Open Source Database Survey report for 2023 during its annual Percona Live conference. According to the survey of nearly 300 database professionals working in companies ranging in size from small-to-medium-sized business to large enterprise, the database market is currently in a period of stasis around database deployments and changes, most likely due to economic uncertainty and post-COVID-19 recovery. The research indicates that most organizations are not planning to make significant alterations to their database strategies over the course of the next three years.

Alongside this broader revelation, the study sheds light on a number of database operations concerns for organizations, including challenges around developer agility, and significant factors driving the choice between deploying open source or proprietary databases.

Findings in the 2023 State of Open Source Database Survey include:

  • More respondents indicate their organizations are doing well with a host of database operations metrics than they are with meeting developer needs:
    • More than 70 percent of respondents say they are doing somewhat or extremely well with database reliability, performance, security, privacy, scalability and backup reliability and integrity.
    • Conversely, meeting the needs of developers placed last on the list of 14 operational metrics collected, with only 55 percent of respondents saying they are doing well in developer agility.
  • Comparing large enterprises and small-to-medium businesses, the research shows that bigger companies tend to have more tools and automation deployed to help their teams:
    • Large enterprises are much more likely to use database monitoring and management solutions, with 93 percent of organizations having such tools in place. Conversely, only 57 percent of small businesses have database monitoring and management solutions deployed.
    • Small companies are much more likely to use on-premises and cloud services to host their databases (49 percent) compared to 26 percent of large enterprises. Large enterprises are also much more likely to use DBaaS offerings (32 percent of deployments).

“Our report indicates that database deployment strategies are expected to remain static for the next few years, with levels of usage remaining consistent across all categories of relational and non-relational databases,” said Joe Brockmeier, Head of Community at Percona. “We’re seeing caution around making significant changes to deployments following the large-scale digital transformation undertaken during the pandemic and the uncertain economic climate the world is facing in 2023. Teams want to improve how they manage, monitor and run those deployments rather than implementing more changes.”

Further findings include:

  • When asked about what drove their choice to use open source databases, respondents most often cited cost reductions (83 percent rated as somewhat or extremely significant) and developer choice (81 percent), followed by faster deployment (75 percent) and then security and more control (73 percent each).
  • For respondents that implemented proprietary databases, the findings are very different – the biggest factors are greater stability (68 percent), more security (63 percent) and regulatory compliance (61).
  • Developer choice was not in the top ten reasons to deploy proprietary databases, pointing to a much larger preference for open source solutions for the developer community.
  • The majority of respondents say their organizations rely on both relational and non-relational databases – 99 percent of respondents run at least one relational database, and 86 percent run at least one non-relational database.
    • MySQL is the most popular relational database, followed by PostgreSQL and Oracle Server at 57, 48 and 47 percent respectively.
    • MongoDB is the most commonly deployed non-relational database, followed by Couchbase and Redis.

“Developers prefer open source software where they have choice and autonomy over how they can architect and build their applications. The flexibility and performance benefits aside, open source also helps companies save on costs compared to running proprietary databases, which can’t be ignored in today’s economy. However, companies can still improve how they run and manage those installations, and that is where Percona can really help,” said Ann Schlemmer, CEO at Percona.

Speakers at this year’s Percona Live will discuss these and other findings from the 2023 survey. Percona Live is sponsored by a range of companies in the data and database markets, including Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver.

If you would like to be notified when the full report from this survey is made available, please send an email with the request to: databasesurvey@percona.com

About Percona

Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries, creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.

Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.

Databases run better with Percona.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005396/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye